FDA records linked by MedtechLedger identify Peerbridge Health, Inc. as the applicant on a single 510(k) record, K253529, with a decision date of September 4, 2026. The submission was received November 13, 2025, and the decision is listed as substantially equivalent. The record carries product code MWJ, regulation number 870.2800, and the device name Peerbridge COR MDx (Cor MDx). The filing address is 3 Columbus Cir. 15th Floor, New York, NY 10019, which is a correspondence address in the filing rather than a verified headquarters. [1][2]

The cleared device and its classification

K253529 covers Peerbridge COR MDx (Cor MDx) under regulation 21 CFR 870.2800, described in the FDA record as an electrocardiograph, ambulatory (without analysis), Class II, product code MWJ, with the cardiovascular advisory committee. The clearance letter lists the regulation name as Medical Magnetic Tape Recorder, a classification label that does not describe the product’s form. The decision code is SESE, meaning substantially equivalent, and the clearance type is abbreviated. [1][2]

The FDA record states that no new clinical testing was required to support substantial equivalence. The letter lists signal characterization, placement accuracy, IEC 60601-2-47, usability under IEC 62366-1:2015+AMD1:2020 and FDA human factors guidance, and battery and power design verification among the supporting materials. [2]

What the manufacturer says the platform does

Peerbridge Health’s own announcement describes Cor MDx as an ambulatory ECG wearable that records continuous, multi-channel ECG for up to 14 days for clinician review, positioned across hospital discharge, home recovery and clinic follow-up. The same announcement states the device removes the need for a separate gateway phone. These are manufacturer descriptions of intended use and design, not independently verified performance. [4]

A company announcement tied to the HIMSS Global Health Conference describes Cor MDx as an IoT ECG wearable and names AT&T wireless connectivity enablement as part of the collaboration. The same announcement states the device would initially be deployed in the COR-INSIGHT clinical trials, with hospital systems in the HeartX program, led by HealthTech Arkansas and MedAxiom, given first access. [6][7]

Research program and regulatory status

Peerbridge Health’s research page describes the COR-INSIGHT trial as optimizing cardiovascular and cardiopulmonary outcomes with AI-driven indications from the Cor ECG wearable, and states IRB approval dated October 11, 2024. The page notes that devices described there are not for sale in the United States and are under clinical investigation. [8]

The ClinicalTrials.gov entry NCT06763549 covers the COR-INSIGHT study and records that it studies a U.S. FDA-regulated device product and an unapproved or uncleared device. That entry describes the investigational context; it does not establish commercial availability of Cor MDx. [9]

How to read the filing record

The linked collection contains one 510(k) record, K253529, and the decision count for the full collection is one substantially equivalent decision; the record sample contains the same single entry. These counts describe the filings retrieved as of the snapshot date and are not measures of company sales, total portfolio or safety performance. No recall records appear in the retrieved sample. [1]

Peerbridge Health, Inc. is the applicant named in the FDA records. No parent, brand owner or corporate affiliate is verified in the numbered sources, and the New York address in the filing should not be read as a confirmed headquarters. Details such as ownership, customer base and commercial launch status remain unknown from these documents. [1][2]